TRVI Stock — Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. (TRVI)

Updated October 16, 2026.

TRVI is a Stock. Total return is 50.6% over the past 7.4 years, 145.2 points behind SPY at 195.8%.

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral nalbuphine formulation intended to treat chronic cough in patients with idiopathic pulmonary fibrosis and other lung conditions; the therapy is currently in phase 2b and phase 2a clinical trials. As an early-stage biotech company without approved products, it does not currently distribute dividends. This stock appeals to investors seeking exposure to clinical-stage drug development with potential for significant upside if trials succeed, though it carries the substantial risk typical of pre-revenue biotechnology companies.

TRVI performance versus SPY

Price and return data through 2026-10-16.

Total return is 50.6% over the past 7.4 years, 145.2 points behind SPY at 195.8%. Over the past year its total return — price change plus distributions reinvested — is 11.8%. Its deepest 1-year drawdown was 39.1%.

TRVI key facts

Asset type

Stock

Asset class

Equity

Inception date

05/07/2019

Distribution frequency

None

Last close

$11.88 (as of 2026-10-16)

Market cap

$1,692,612,991

Average volume

2704402.0

Beta

1.046

Payout ratio

0.0%

EPS

$-0.35

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TRVI risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 39.1%.

Who may consider TRVI — and who may not

It is a weaker fit for investors who need monthly cash flow (TRVI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on TRVI

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions